Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02740179 · ClinicalTrials.gov registry record · NA
Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study)
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT02740179: Completed NA study, sponsored by Massachusetts General Hospital.
NCT02740179 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02740179, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
HIV-infected individuals treated with antiretroviral medications are living longer, but have an increased risk of heart disease when compared to non-HIV-infected individuals. A hormone called aldosterone, which regulates blood pressure and sodium balance, is elevated in the HIV population in association with with increased belly fat and altered glucose metabolism. Elevations in aldosterone hormone may also be associated with abnormal blood flow, inflammation, and coronary plaque in the heart. This study is being conducted to evaluate whether therapies to reduce the actions of aldosterone may decrease the burden and progression of heart disease in the HIV population.
Interventions
- DRUG Placebo
- BEHAVIORAL Lifestyle Modification
- DRUG Eplerenone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2017-01 |
| Est. Completion | 2022-03-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02740179
The ClinicalTrials.gov registry entry for NCT02740179 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02740179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02740179 about?
NCT02740179 is a clinical study titled "Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study)". HIV-infected individuals treated with antiretroviral medications are living longer, but have an increased risk of heart disease when compared to non-HIV-infected individuals. A hormone called aldosterone, which regulates blood pressure and sodium balance, is elevated in the HIV population in associa...
What is the current status of trial NCT02740179?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2017-01. Estimated completion is 2022-03-17.
What interventions are being tested in trial NCT02740179?
The interventions under investigation include: Placebo (DRUG), Lifestyle Modification (BEHAVIORAL), Eplerenone (DRUG).
Who is sponsoring clinical trial NCT02740179?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.